Overview

Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome

Status:
Unknown status

Trial end date:
2012-10-01

Target enrollment:

Participant gender:

Summary

Polycystic ovary syndrome (PCOS) is often associated with pathological conditions, such as insulin resistance (IR), type 2 diabetes (DM2), obesity and it has potentially increased risk for cardiovascular disease (CVD). Of note, risk factors for CVD including dyslipidaemia, hypertension, oxidative stress and inflammation are associated with PCOS. The investigators want to evaluate the effects of two different types of E/P therapy on cardiovascular risk in PCOS.

Phase:

Phase 1

Details

Lead Sponsor:

Catholic University of the Sacred Heart

Treatments:

Drospirenone
Drospirenone and ethinyl estradiol combination
Estradiol
Ethinyl Estradiol